Omeros Logo     Print Page  |  Close Window

2016 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
2016 | 2015 | 2014 | 2013 | 2012 | 2011
01/15/16Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference
SEATTLE--(BUSINESS WIRE)--Jan. 15, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% will be the focus of a series of ... 
 Printer Friendly Version
01/06/16Omeros Announces $70 Million New Credit Facility and Conversion of Contract Sales Force to In-House Team
SEATTLE--(BUSINESS WIRE)--Jan. 6, 2016-- Omeros Corporation (NASDAQ:OMER) today announced that it has closed a non-dilutive senior credit facility with Oxford Finance and East West Bank. The new credit facility consists of a $50.0 million term loan drawn by the company at closing and the ability, subject to the satisfaction of certain conditions including achievement of certain net revenue milestones for the company’s product Omidria® (phenylephri... 
 Printer Friendly Version